GOVX : Summary for GEOVAX LABS INC COM STK USD0.01 - Yahoo Finance

U.S. Markets open in 5 hrs 16 mins

GeoVax Labs, Inc. (GOVX)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.07-0.00 (-3.68%)
At close: 3:49 PM EST
People also watch:
SNGXHDVYADLSAEMDIBIO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close0.07
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume210,864
Market Cap3.22M
Beta-0.26
PE Ratio (TTM)-0.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Marketwired19 hours ago

    GeoVax to Present at Keystone Symposia on Hemorrhagic Fever Viruses

    GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, announced today that its Senior Vice President of Research and Development, Dr. Farshad Guirakhoo, will give a talk ...

  • Marketwired5 days ago

    GeoVax Observes World AIDS Day

    In recognition of World AIDS Day on December 1, GeoVax Labs, Inc. , a biotechnology company specializing in developing human vaccines, encourages everyone to get tested for HIV, the virus that causes AIDS....

  • Zacks Small Cap Research15 days ago

    GOVX: Update on Third Quarter Financials

    Total revenue was $440,106 for the three-month ended September 30, 2016, which was related to grants from the NIH in support of its HIV/AIDS vaccine development efforts. R&D expenses were $683,939 for 3Q16, as compared to $378,521 for the comparable period of 2015. R&D expenses included direct costs funded by NIH grants, as well as other vaccine manufacturing and testing costs. G&A expenses were $220,707 for the three month ended September 31, 2016, as compared to $335,932 for the comparable period of 2015.